"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Deke Slayton Cancer Center conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 17 clinical trials were completed, i.e. on average, 89.5% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 8 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Deke Slayton Cancer Center" #1 sponsor was "US Oncology Research" with 9 trials, followed by "Celgene" with 4 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored, "Pfizer" with 3 trials sponsored and "Bristol-Myers Squibb" with 3 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Deke Slayton Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 5 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "NRG Oncology" with 2 trials as a collaborator and "Pfizer" with 2 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Deke Slayton Cancer Center" are "Breast Cancer" (7 trials), "Prostate Cancer" (6 trials), "Metastatic Breast Cancer" (3 trials), "Non-Small Cell Lung Cancer" (3 trials) and "Small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "Deke Slayton Cancer Center" in a lesser frequency.

Most popular intervention types in "Deke Slayton Cancer Center" are "Drug" (39 trials), "Other" (5 trials), "Radiation" (5 trials), "Biological" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (5 trials), "Carboplatin" (4 trials), "Amrubicin" (3 trials), "Docetaxel" (3 trials) and "Laboratory Biomarker Analysis" (3 trials). Other intervention names were less common.

The vast majority of trials in "Deke Slayton Cancer Center" are 28 trials for "All" genders, 11 trials for "Male" genders and 8 trials for "Female" genders.

Currently, there are NaN active trials in "Deke Slayton Cancer Center". undefined are not yet recruiting, 4 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Deke Slayton Cancer Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Deke Slayton Cancer Center, 1 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".